BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 8, 2025
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» KSI-501 bispecific antibody shows superiority to current anti-VEGF therapies in preclinical studies
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Ocular
KSI-501 bispecific antibody shows superiority to current anti-VEGF therapies in preclinical studies
Feb. 15, 2023
No Comments
Retinal disorders such as diabetic macular edema (DME), wet age-related macular degeneration (wAMD) or uveitic macular edema share inflammatory traits mediated by vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6), among others.
BioWorld Science
Conferences
Ocular